Flavivirus Host-Range Mutations for Safe Vaccine Development
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against flaviviruses, such as Dengue virus, have shown limited success in providing immunity against these arthropod-vectored viruses, which are prevalent in tropical and subtropical regions and pose significant public health threats due to their ability to replicate in both insect and mammalian hosts, making it challenging to develop effective vaccines.
Innovation Solution
The development of modified flavivirus envelope proteins with mutations in the N-terminal transmembrane domain, specifically a proline substitution in the E protein's E-T1 domain, which allows the virus to replicate and assemble in insect cells but not in mammalian cells, creating a host-range mutant that can induce immunity without causing disease in humans.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type flavivirus is used as a vaccine, then immunity against the virus is provided, but the virus can cause disease in human hosts
Solution Approach 1:
The patent applies parameter changes by introducing specific point mutations (e.g., G460P, G467P) in the envelope protein's transmembrane domain of the flavivirus. These mutations alter the viral properties to restrict host range to insect cells while maintaining mammalian cell infection capability for vaccine development, thereby changing the virus from pathogenic to safe vaccine candidate
Solution Approach 2:
The patent applies local quality by making targeted modifications specifically in the N-terminal transmembrane domain (E-T1 domain) of the envelope protein, while leaving the rest of the viral genome and other protein structures unchanged. This localized mutation approach allows selective alteration of host range properties without compromising overall viral structure or immunogenicity
2Object-affected harmful factors
If the virus is modified to replicate only in insect cells, then safety in human hosts is improved, but the ability to induce immunity in mammals is reduced
Solution Approach 1:
The patent uses an intermediary approach by creating a viral strain that can replicate in both insect and mammalian cells during the vaccine development process, but restricts replication to insect cells when administered to humans. The modified envelope protein acts as an intermediary mechanism that enables this selective replication behavior, allowing the virus to serve as a safe vaccine candidate that still elicits immune responses in mammals
3Adaptability or versatility
If mutations are introduced in the transmembrane domain, then host range is restricted to insect cells, but the virus assembly in mammalian cells is impaired
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid substitutions (e.g., glycine to proline) at defined positions (G460P, G467P) in the E-T1 domain. These parameter changes in the transmembrane domain alter the virus's host range specificity to prefer insect cells while maintaining sufficient functionality for vaccine production in mammalian cell lines
Data Source
AI summary
Methods and compositions concerning mutant flaviviruses with host-range phenotypes are provided. Nucleotide sequences that encode mutant flavivirus proteins are also provided. In certain aspects, viruses comprising these sequences display reduced replication in mammalian cells. In further aspects of the invention, flavivirus vaccine compositions and methods for vaccination against flavivirus infection are provided.